Plain-English translation of NCT07630649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new gene therapy called ixoberogene soroparvovec (Ixo-vec), which is designed to treat wet age-related macular degeneration—a condition that causes vision loss due to abnormal blood vessel growth in the eye. Instead of needing repeated injections, this single injection aims to produce a protein that protects your vision over time. The study focuses on whether this medication is safe and works well when given to the second eye in people who have already received it in one eye, or in people new to the treatment.
Currently, people with wet macular degeneration need repeated injections of anti-VEGF drugs to control abnormal blood vessel growth. This trial exists to see whether this medication—a one-time injection that may provide long-lasting protection—could reduce the burden of repeated treatments and help preserve vision in both eyes.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the new medication into your second eye. Some participants will have already received this treatment in their first eye during a prior study; others will be receiving it for the first time in both eyes at different time points. The study will track your vision and eye health over time with regular visits to check for safety and effectiveness, and to see whether you need additional anti-VEGF treatments. The study involves multiple visits at specialized eye care centers, with the exact timeline to be discussed with the research team.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States